All News

As survivors, sometimes we step outside our comfort zones to help groups that raise awareness about cancer along with funds for research. Representing survivorship at a Relay for Life event can be as important as donating funds or decorating luminaries.

Do I have cancer? Did I have cancer? I may have an answer.

Malignant tumors of the brain or spinal cord represent about 1 percent of all cancers. Michael Feuerstein, Ph.D., M.P.H., is among that small percentage.

Many survivors of Ewing sarcoma have few complications and long-term side effects later on, according to a recent study.

According to lead investigator Lillian L. Siu, M.D., the IDO1 inhibitor BMS-986205 had “best-in-class” activity for patients with advanced tumors in a phase 1/2a study.

Despite the incidence of breast cancer either holding steady or decreasing in other U.S. racial/ethnic groups, it has been increasing in Asian-American women for the past 25 years.

Finding normalcy after cancer.

Sometimes I’m referred to as a cancer "survivor," but I just don’t see myself as such.

Ed has bone marrow biopsy, and the results are surprising.

Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a randomized, double-blind phase 3 study that compared 10 mg/kg Yervoy (ipilimumab) or a lower dose of the anti-CTLA-4 anticlonal antibody.

The USPSTF may be changing its stance on PSA screening for prostate cancer.

Androgen deprivation therapy, a popular treatment for prostate cancer, may have a link to dementia, according to a recent analysis.

What do you say when people remark to you that you look great or that there is no way you just had cancer or chemo?

Breast cancer survivor looks back and describes her radiation treatment and shares her tips.

Novel combinations may be on the rise for the treatment of mantle cell lymphoma.

The PD-1 inhibitor, Opdivo, may be a promising option for patients with advanced anal cancer, according to a recent study.

Patients with early, HER2-positive breast cancer were found to be more likely to respond to the dual HER2-blockade, according to a recent study.

Offering love and support to a loved one going through cancer is one of the best ways to show you care.

We have all attributed a slip of the tongue or a forgetful moment to chemobrain and then laughed.

Did you know that naked mole rats are immune to cancer? Here's a weekly roundup of #CureFact

Shana Wingo, M.D., discusses surgery's changing role in the treatment of ovarian cancer.

While other tumor types have seen extraordinary progress with immunotherapy agents such as Opdivo (nivolumab) and Yervoy (ipilimumab), they have not yet shown similar success in the treatment of prostate cancer. Padmanee Sharma, M.D., Ph.D., weighs in.

The American Society for Clinical Oncology (ASCO) recently published a set of recommendations to better care for patients who are sexual and gender minorities.

Efforts to boost Ed's immune system begin to work.

Appointment time, arriving early, and six other easy things you can do to optimize your time with the oncologist

A two-time cancer survivor, breast cancer and melanoma, discusses the empty nest process and cancer.

Laura Yeager, breast cancer survivor, reflects on her journey and life as a survivor in her prose poem “On Losing My Nipples.”

In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.

In an interview with CURE at the Interdisciplinary Prostate Cancer Congress, Celesita Higano, M.D., discussed the early use of chemotherapy, the potential for PARP inhibitors and the evolving role of radium-223 in prostate cancer.

In an interview with CURE, Leena Gandhi, M.D., Ph.D., discussed emerging developments in the first-line treatment for patients with ALK-positive NSCLC, as well as novel agents emerging in the field.